GlaxoSmithKline's rosiglitazone (Avandia) will receive a black box warning by the FDA because of concerns over heart failure associated with use of the drug.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content